Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Feb 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell

This review aimed to compare the safety and effectiveness of first-line treatments for mantle cell lymphoma. The authors concluded that newer treatments improve outcomes for younger transplant eligible patients and elderly transplant-ineligible patients. 

Some background

Mantle cell lymphoma (MCL) is a rare form of non-Hodgkin’s lymphoma (NHL). It is an aggressive type of NHL, with poor outcomes. Treatments for MCL have evolved during recent years. However, the optimal treatment regimens for patients with MCL are still unknown.  

Methods & findings

This review analyzed data from 9 randomized control trials (RCTs) and 20 non-randomized interventional studies on the safety and effectiveness of first-line therapies for MCL.  

In elderly patients that were not fit for stem cell transplant (SCT), response to chemotherapy regimens varied from 65% to 100%. The best responses were seen with BR (bendamustine and rituximab) and cytarabine (Cytosar-U). The overall survival (OS) in these patients ranged from 40 months to 69.6 months. Patients had an OS of 69.6 months when they received rituximab (Rituxan) maintenance therapy (treatment meant to delay or prevent disease relapse).

In younger transplant-eligible patients, the overall response ranged between 64-100%. The best response (100%) was reported in patients receiving ibrutinib (Imbruvica) and rituximab. OS ranged from 81.6 months to 152.4 months.  

The most common side effect reported in most trials was low white blood cell counts (neutropenia). The rates for this side effect ranged from 24% with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) to 85% with VR-CAP (bortezomib, rituximab, cyclophosphamide, epirubicin, and prednisone).

The bottom line

This review concluded that newer treatments improved the outcomes for patients with MCL. The authors suggested that future chemotherapy-free regimens may be promising. 

Published By :

Critical reviews in oncology/hematology

Date :

Dec 28, 2020

Original Title :

Clinical efficacy and safety of first-line treatments in patients with mantle cell lymphoma: a systematic literature review.

click here to get personalized updates